Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers. Senior Personal Finance Correspondent Sharon ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...
One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...
While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...
The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the second round of drug price negotiations, made possible through the Inflation | ...
The most negatively impacted sectors are frozen, refrigerated, general food and beverages. Circana found GLP-1 users’ monthly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback